US EditionAthira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates - Athira Pharma (NASDAQ:ATHA)
Summary by Benzinga
1 Articles
1 Articles
All
Left
Center
1
Right
Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates - Athira Pharma (NASDAQ:ATHA)
Completed healthy volunteer Phase 1 clinical study of ATH-1105 as a potential treatment for amyotrophic lateral sclerosis (ALS); full healthy volunteer data expected in 2H25 On-track to enable dosing ALS patients in late 2025 BOTHELL, Wash., May 09, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, tod…
·New York, United States
Read Full ArticleCoverage Details
Total News Sources1
Leaning Left0Leaning Right0Center1Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
